S
Andrin Oswald
Global Head of Development Franchises, Novartis
GLOBAL: Was a Red Cross delegate in Nepal
FORMERLY: Country head for South Korea
With only eight years in the industry, Andrin Oswald, MD, has clearly been fast-tracked for approval. Early-on, Oswald, 37, traded his MD coat for a business suit, then left McKinsey for the International Red Cross in Nepal. "I pursued learning opportunities," he says. "Sometimes a step that seemed unusual turned out to be a great asset in the next role."
Andrin Oswald
Oswald is no stranger to the executive suite, having started out as assistant to CEO Dani Vasella. Soon he was dispatched to South Korea as country head, just as new trade packs were unlocking that fast-growing market. But in the wake of FDA knockdowns of Galvus, Prexige, and Zelnorm, Oswald was called back to HQ to help execute new pharma chief Joe Jimenez's development model.
Like many docs who join pharma, Oswald says his passion is to reach suffering people. He should be in hog heaven with Novartis' 20 NDAs due on deck by 2010 and 150 compounds currently in the pipeline. He may also be in the horse race to become the next CEO; should Vasella, 54, decide to kick back after making the new revolution at Novartis, it wouldn't be unusual to expect a successor in his own mold: a pharma exec with a physician's sensibility with one eye on his company's stock value, the other on its social value.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.